MicroRNAs as molecular markers in lung cancer by Silva, Javier et al.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Silva et al. ISSN 2330-4049
Javier Silva1, Vanesa Garcia1, Ana Lopez-Gonzalez2, Mariano Provencio1
1Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda-Madrid, Spain
2Medical Oncology Department, Complejo Asistencial Universitario de León, Spain
Received September 04, 2013; Revised October 04, 2013; Accepted October 07, 2013; Published Online October 10, 2013
Review Article
Abstract
Lung cancer is the most common cause of cancer death in the western world for both men and women. Lung cancer appears to
be a perfect candidate for a screening program, since it is the number one cancer killer, it has a long preclinical phase, curative
treatment for the minority of patients who are diagnosed early and a target population at risk (smokers) and it is also a major
economic burden. The earliest approaches to identifying cancer markers were based on preliminary clinical or pathological
observations, although molecular biology is a strong candidate for occupying a place among the set of methods. In search of
markers, several alterations, such as mutations, loss of heterozygosity, microsatellite instability, DNA methylation, mitochon-
drial DNA mutations, viral DNA, modified expression of mRNA, miRNA and proteins, and structurally altered proteins have all
been analysed. MicroRNAs (miRNA) are small RNA molecules, about 19-25 nucleotides long and encoded in genomes of plants,
animals, fungi and viruses. It has been reported that miRNAs may have multiple functions in lung development and that aber-
rant expression of miRNAs could induce lung tumorigenesis. We review here the role of miRNAs in lung tumorigenesis and
also as a novel type of biomarker.
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Introduction
Lung cancer is the most common cause of cancer death in
the western world for both men and women.1 Each year the
number of lung cancer deaths is greater than the number of
deaths from breast, prostate and colorectal cancer com-
bined.2 In 2007, estimates calculated 213,380 new cases of
lung cancer and 160,390 deaths, accounting for 15% and
29%, respectively, of all cases of cancer.2 Clinically, lung
cancer can be divided into 2 groups: small cell lung cancer
(SCLC) and non-small cell lung cancer (NSCLC), which of-
ten have different specific genetic alterations.3 Approxi-
mately 75% of lung tumours are NSCLC, which includes
squamous cell carcinoma, adenocarcinoma and large cell
carcinoma.1 SCLC is characterized by its rapid growth, early
dissemination and chemosensitivity andradiosensitivity.4
Over 80% of lung cancers are attributable to cigarette smok-
ing5, with a risk directly proportional to consumption. Thus,
cessation of smoking remains the single most important in-
tervention for lung cancer prevention: recently some pro-
gress has been made by the introduction of smoking bans in
public places throughout Europe. Although the exposure to
tobacco carcinogens is known to be the main risk factor for
lung cancer, only a minority of heavy smokers will develop
this disease6, suggesting environmental or genetic determi-
nants in disease initiation and progression. Thus, in-
ter-individual differences in carcinogen metabolism may
play an essential role in the development of this environ-
mental cancer.7 In addition, with the increasing incidence of
non-smoking-related lung cancers, particularly in women,
the identification of high-risk groups among non-smokers
will be an important challenge.8
Whereas screening the general population has been recom-
mended for other common cancers, including breast, colo-
rectal and possibly prostate cancer, no such recommendation
currently exists for lung cancer.9 Only between 10-16% of
lung cancer patients survive more than 5 years.2 The dismal
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prognosis of lung cancer is largely related to the fact that this
tumour is generally diagnosed at a late stage. However, out-
come is significantly better in patients diagnosed early, with
the 5-year survival rate of stage 1 lung cancer at 60-70%.10
Early detection of lung cancer could change disease outcome,
although current diagnostic tools are either too costly or not
sensitive enough to allow early detection.11, 12 For all these
reasons, it is essential to develop an effective screening regi-
men for this disease.
Lung cancer appears to be a perfect candidate for a screening
program, since it is the number one cancer killer, it has a
long preclinical phase, curative treatment for the minority of
patients who are diagnosed early and a target population at
risk (smokers) and it is also a major economic burden.
Molecular markers
The progression from pre-neoplasia to cancer is accompanied
by the accumulation of genetic and epigenetic alterations.
These lead to altered expression patterns and modifications
in protein structure and function. The changes can be used
as molecular tumour markers, being useful in: a) characteri-
zation of a predisposition or genetic susceptibility to suffer-
ing neoplasia; b) detection of cancer at early stages or
pre-malignant phases; c) the evaluation of disease outcome;
d) monitoring of disease progression; and e) determination of
response to therapy, so favouring a better choice of therapy
for each patient.
Currently, the diagnostic tools for lung carcinoma are: chest
X-ray, computed tomography (CT), cytological analysis of
sputum and bronchoalveolar lavage fluid, and spiral CT,
among others. However, to develop more strategies, diagno-
sis, prognosis and treatment need to be improved. The goal
of clinical and potential molecular markers is to develop a
clinical screening test that would be useful and practical in
clinical practice, complementing the use of imaging modali-
ties such as spiral CT.
The earliest approaches to identifying cancer markers were
based on preliminary clinical or pathological observations13,
although molecular biology is a strong candidate for occu-
pying a place among the set of methods. In search of mark-
ers, several alterations, such as mutations, loss of heterozy-
gosity, microsatellite instability, DNA methylation, mito-
chondrial DNA mutations, viral DNA, modified expression
of mRNA, miRNA and proteins, and structurally altered
proteins have all been analyzed. High-throughput screening
approaches that analyze expression patterns of several genes
and proteins have been used to search for cancer-associated
molecules.13 In lung carcinomas several alterations have been
found, such as KRAS mutated in approximately 30% of
cases14, over-expression of C-erbB2 (Her-2/neu) or BCL2 in
25% of cases14 and DLC1 (deleted in lung cancer 1) altered in
27% of primary NSCLC.15
In clinical practice, there are several molecular tumour
markers used for screening in some tumour types, such as
serum carcino-embryonic antigen (CEA) in colorectal can-
cer16 and prostate-specific antigen (PSA) in prostate cancer.17
However, these markers are not very sensitive in premalig-
nant or early stages or are not specific to malignancy. For
most other types of cancer, such as early-stage lung cancer,
there are no molecular markers available in clinical practice.
Although many effective cancer therapies have recently
been developed, there are only a few molecular markers that
are available at present for determining treatment response.
For example, breast cancer cells that express high levels of
the tyrosine receptor kinase are more likely to respond to
trastuzumab.18 In lung cancer, the ability to predict re-
sponses to chemotherapy or targeted agents is extremely
limited and is based on tumour histology alone. Therefore,
we are unable to identify a priori the right treatment regi-
men for each tumour. Appropriate molecular markers could
predict response to specific treatments. An example is the
use of epithelial growth factor tyrosine kinase inhibitors
(EGFR-TKIs) in lung cancer.19 Although more studies are
necessary, it has been described that a series of mutations in
EGFR makes tumours highly sensitive to this form of ther-
apy. Thus, detection of these mutations could identify a
group of patients who derive great benefit from EGFR-TKI
therapy.19 Another example is the use of molecular markers
in relation to cisplatin treatment. Only a proportion of lung
cancer patients will respond to this chemotherapy treatment,
whose adverse side-effects are significant. Cisplatin needs to
bind to DNA, creating platinum-DNA adducts, which can be
repaired by nucleotide excision. Patients with completely
resected NSCLC and ERCC1-negative tumours (enzyme with
central role in DNA repair) appear to benefit from adjuvant
cisplatin-based chemotherapy, whereas patients with
ERCC1-positive tumours do not.20
microRNAs as molecular markers
MicroRNAs (miRNA) are small RNA molecules, about 19-25
nucleotides long and encoded in genomes of plants, animals,
fungi and viruses.
miRNAs constitute a highly conserved class of naturally oc-
curring non-coding single-stranded RNA molecules, which
function as post-transcriptional negative gene regulators of
complementary target mRNAs. Although they may differ in
distinct organisms, the basic process involves a transcription
of dsRNA that is processed into shorter units that mediate
target recognition in a sequence-specific manner (Table 1).21
It has been calculated that between 74% and 92% of the
gene transcripts are probably under miRNA control.22, 23
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TABLE 1:Main Studies that have investigated miRNA in lung cancer
Yanaihara et al. Cancer Cell. 2006
Lu et al. Proc Am Thorac Soc. 2008
Fabbri et al. Proc Natl Acad Sci. 2007
Inamura et al. Lung Cancer. 2007
Yu et al. Cancer Cell. 2008
Fagi F. Thorac Surg Clin. 2012
Rabinowits et al. Clin Lung Cancer. 2009
Hu et al. J Clin Oncol. 2010
Hennessey et al. PLoS One. 2012
Bianchi et al. E cancer medical science. 2012
Matsubara et al. Oncogene. 2007
Shen et al. Lab Invest. 2011
Rani et al. Cancer Biol. Ther. 2013
Xu et al. Clin Transl Oncol. 2013
Zhang et al. Med Oncol. 2013
miRNAs are specifically expressed or greatly enriched in a
particular organ, implying an organ- or tissue-specific func-
tion. Furthermore, expression profiles of miRNAs in mice
and human lung are very similar, indicating evolutionary
conservation of miRNA expression.24, 25 It has been reported
that lung is one of the tissues with the most abundant ex-






There are several human diseases, such as spinal muscular
atrophy, Parkinson’s disease, fragile X mental retardation or
DiGeorge syndrome, in which miRNAs or their processing
might be involved.27-29 Among human diseases, it is
well-known that miRNAs are aberrantly expressed in nu-
merous human cancers, including colon, breast, ovarian,
prostate and lung cancer30, 31 (Figure 1). Moreover, since a
single miRNA may have as many as a few thousand target
genes with different biological entities, the data obtained
from miRNA profiling may provide information that can be
used to classify more accurately the different cancer subtypes
described to date. Besides regulating the expression of
known oncogenes and tumour suppressors, miRNAs also act
as oncogenes and tumour suppressors directly, which pro-
vides an apparent connection between the altered expression
of miRNAs and cancer development. Thus,
miRNA-expression profile of human tumours is closely asso-
ciated with diagnosis, staging, progression, prognosis and
response to treatment.31-33
In the case of lung cancer, it has been reported that miRNAs
may have multiple functions in lung development and that
aberrant expression of miRNAs could induce lung tumori-
genesis.34, 35 Moreover, as mentioned above, the different
expression profiles of miRNAs between normal lung and
lung cancer has led to their emergence as a novel type of
biomarker. This may be helpful for lung cancer diagnosis and
therapy using miRNAs as novel therapeutic targets.36, 37
The current diagnostic tools available for lung cancer often
lack sensitivity and the ability to distinguish different lung
cancer subtypes, such as NSCLC and SCLC or adenocarci-
noma and squamous cell carcinoma.38, 39 In this respect, the
applicability of miRNA-based biomarkers may improve
methodology for both sensitivity and specificity. Differently
expressed miR-29 (a, b and c), miR-99b, miR-102, let-7a-2
and let-7f-1 have been used to discriminate histological types
of lung carcinomas.32, 40 As well as data strongly supporting
the view that miRNAs work as biomarkers for differentiating
lung cancer, the expression of miRNA signatures has been
linked to the prognosis of lung cancer. Deregulated expres-
sion of the let-7 family has been frequently described in dif-
ferent analyses of miRNA expression signatures in lung can-
cer. The decrease in the let-7 family is associated with worse
prognosis and shortened survival, which supports the view
that it has a tumour suppression function.41-43 Deregulated
miRNA has been also related with lymph node metastasis
and advanced clinical stage.44
Talking about EGFR-TKIs, we know that patients with acti-
vating EGFR mutations eventually develop resistance to this
drugs. It is thought that a secondary mutation in the EGFR
gene, such as T790M, or amplification of the MET
proto-oncogene could be implicated. Recently, upregulated
miR-214 has been related to acquired resistance to gefitinib,
via PTEN/AKT signalling pathway.45
MicroRNAs in plasma from cancer pa-
tients
The presence in plasma or serum of circulating nucleic acids
(DNA and RNA) released by tumour cells increases the pos-
sibility of detecting alterations associated with the tumour
and could be used as a tumour marker. Furthermore, as cir-
culating nucleic acids are a source of tumour information
obtained through a non-invasive and rapid method, samples
could be taken at different times during follow-up to identify
residual disease and recurrence at asymptomatic stages.
MiRNAs originating in several tumour tissues enter circula-
tion and can be detected in serum. The fact that plasma con-
tains large amounts of stable miRNAs implies a great poten-
tial of serum miRNA profiling as the fingerprint for disease.46
Regarding the release mechanism of nucleic acids from tu-
mour cells to the bloodstream, we recently reported that a
major fraction of these molecules detected in plasma of can-
FIG. 1: miRNA function
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cer patients are highly protected in tumour-specific mi-
crovesicle-like structures.47 In other studies, cancer-specific
miRNAs with high resistance to RNases and harsh conditions
were identified in plasma or serum of cancer patients46, 48-52,
showing that the high stability conferred by its parti-
cle-associated features makes miRNA levels well suited for
being tested as non-invasive cancer biomarkers in patient
plasma samples.  Moreover, other studies have suggested
that miRNAs contained in tumour vesicles are functional
and suppress target mRNAs for signal transduction compo-
nents within recipient cells.53
Recently, our group as well as other research groups have
analysed serum miRNA profiles of lung cancer patients to
evaluate their potential use in predicting diagnosis and
prognosis of disease.46, 54, 55 Employing Solexa sequencing
analysis, the Chen et al.46 identified specific expression pat-
terns of serum miRNAs for lung cancer in the Chinese popu-
lation. They provided evidence that serum miRNAs con-
tained fingerprints for different cancer types. Most differ-
ently expressed miRNAS in lung cancer included miR-205
and miR-206 that were previously involved in tumorigenic
processes such as cell division and cell growth. Similarly,
Lodes et al. focused their study on the evaluation of miRNA
expression profiles in human serum for five types of human
tumours, including lung cancer, using a pan-human mi-
croRNA high-density microarray. They found that these
expression patterns could be used to distinguish between
normal and cancer patient samples and, furthermore, that
one millilitre of serum contained sufficient miRNAs to de-
tect these expression patterns, without requiring amplifica-
tion techniques. In a recent study, Hu’s group analyzed the
differences in levels of serum miRNAs between 30 NSCLC
patients with longer survival and 30 patients with shorter
survival. Using Solexa sequencing, they found 11 differently
altered miRNAs between longer-survival and
shorter-survival groups and, moreover, levels of 4 of them
(miR-1, miR-30d, miR-486 and miR499) were significantly
associated with overall survival.
Recently, a phase I//II biomarker study has been published,
in which serum miRNA using PCR was examined from 30
NSCLC patients and 20 healthy controls. A combination of
two differentially expressed miRNAs miR-15b and miR-27b
was able to discriminate NSCLC from healthy controls.56
Combining serum mi-RNA detection and low-dose com-
puted tomography (LD-CT) could be an interesting screening
test. Real-time PCR was used to identify the profile of
miRNAs extracted from the serum of asymptomatic
LD-CT-detected lung adenocarcinoma and normal serum. A
multivariate risk-predictor was developed based on 34
miRNA expression levels. When the predictor was tested on
an independent cohort of patients with asymptomatic LD-CT
detected lung cancer, it displayed an overall accuracy of 80%
(sensitivity 71%, specificity 90%), and more important, the
risk-predictor was able to distinguish between
LD-CT-detected benign nodules and malignant disease.57 We
agree with the relevance of this last point, due to the relative
high number of benign lung nodules detected by LD-CT
screening.
Conclusion
miRNAs are frequently altered in many types of tumours,
including lung carcinoma. Their expression patterns are as-
sociated with the classification and prognosis of these tu-
mours. That miRNAs are stable in plasma from lung cancer
patients supports their use as important clinical biomarkers58,
59, 60detectable in peripheral blood associated with tumour.
The fact that certain miRNAs have an oncogenic function
while others have a role as tumour suppressors is especially
relevant in terms of their applicability in anti-tumour thera-
pies. Thus, oncogenic miRNAs would require therapies in-
hibiting their function, while those therapies for miRNAs
with tumour suppressor ability should increase miRNA ac-
tivity in cancer cells. There are some studies that analyze the
potential of miRNA-based therapies in cancer.61, 62
In summary, the expression of miRNA signatures in plasma
from lung cancer patients can be used as new markers, ob-
tained by a non-invasive method, for disease diagnosis and
prognosis. They have higher specificity and sensitivity than
analyses used currently.
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